SCHEMBL24348943

SCHEMBL24348943

COC(=O)NCc1nc(C)c(-c2csc(-c3ccc(O)c(F)c3F)n2)s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 3/20 0.67
▸ OPRM1 P35372 1/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ GAA P10253 3/20 0.35
▸ XDH P47989 1/20 0.35
▸ MAPT P10636 4/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ NPSR1 Q6W5P4 3/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ HPGD P15428 3/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ PIK3CG P48736 3/20 0.34
▸ LMNA P02545 3/20 0.33
▸ HTT P42858 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24349281 0.90 BPGM (0.62) BPGMOPRM1MEN1KMT2AGAA
SCHEMBL24348548 0.85 BPGM (0.77) BPGMOPRM1MEN1KMT2AGAA
SCHEMBL24271952 0.85 BPGM (0.68) BPGMMEN1KMT2AGAAXDH
SCHEMBL24348538 0.85 BPGM (0.65) BPGMMEN1KMT2AGAAXDH
SCHEMBL24348948 0.84 BPGM (0.73) BPGMOPRM1MEN1KMT2AGAA
SCHEMBL24349409 0.83 BPGM (0.66) BPGMOPRM1MEN1KMT2AGAA
SCHEMBL24272009 0.82 BPGM (0.64) BPGMMEN1KMT2AGAAMAPT
SCHEMBL24348944 0.81 BPGM (0.68) BPGMOPRM1MEN1KMT2AGAA
SCHEMBL24271879 0.81 BPGM (0.66) BPGMMEN1KMT2AGAAXDH
SCHEMBL24271967 0.81 BPGM (0.65) BPGMOPRM1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 BPGM 1/4885OPRM1 597/4885MEN1 3560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback